ClinicalTrials.gg
TerminatedNCT01524887Updated May 19, 2021Results posted

Phase 3 IGIV, 10% in Alzheimer´s Disease

A Phase 3 interventional study of Immune Globulin Intravenous (Human), 10% Solution and Human albumin 0.25% in Alzheimer´s Disease, sponsored by Baxalta now part of Shire. Terminated at 69 sites in 8 countries. Open to participants aged 50 Years to 89 Years. Per ClinicalTrials.gov, last updated 2021-05-19.

Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was terminated because the first Phase 3 did not demonstrate efficacy on the co-primary endpoints. The known safety profile remained unchanged.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
508
Allocation
Randomized
Ages
50 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
181st of 1,609
508 · median 73
Started
2012
with 61 others
Phase 3
188 of 1,940
19 open now
Registered
491st of 1,940
by date

Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 181st largest by enrollment of the 1,609 interventional ones that give a count, is one of 62 that started in 2012, is one of 188 in phase 3, and was the 491st registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years to 89 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,940 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to provide evidence of efficacy and safety to support the development of IGIV, 10% as a treatment option for patients with mild to moderate Alzheimer´s Disease.

03

Conditions studied

  • Alzheimer´s Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Males or females of age 50 to 89 years inclusive at the time of screening
  • Written obtained from either the subject or the subject's legally authorized representative prior to any study-related procedures
  • Written informed consent obtained from an able and competent caregiver who is willing to comply with the requirements of the protocol pertaining to him/her, including facilitating the subject's participation in the study
  • Diagnosis of Probable Alzheimer´s Disease (AD) according to NINCDS-ADRDA* 1984 criteria (* National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders Association)
  • Dementia of mild to moderate severity ( [MMSE] 16-26 inclusive at the time of screening)
  • Neuroimaging (computed tomography [CT] or MRI) performed after symptom onset consistent with AD diagnosis
  • Willingness to comply with the requirements of the protocol and ability to comply with testing and infusion regimen, including adequate corrected visual acuity and hearing ability
  • For at least 12 weeks prior to screening, on stable doses of AD medication(s) approved by local regulatory authorities. Subjects must not be on two acetylcholinesterase inhibitors concurrently.
  • Venous access for repeated infusion and phlebotomy
  • If receiving psychoactive medications (eg, antidepressants other than monoamine oxidase inhibitors [MAOIs] and most tricyclics, antipsychotics, anxiolytics, anticonvulsants, mood stabilizers, etc.), must be on stable doses for at least 6 weeks prior to screening
  • For women of , the subject must have a negative pregnancy test at screening and must agree to employ adequate measures (eg, birth control pills/patches, intrauterine device, or diaphragm or condom [for male partner] with spermicidal jelly or foam) throughout the course of the study
  • For subjects with a coronary artery stent, the subject must receive documented medical clearance from an interventional cardiologist stating that the subject is not at increased risk for stent occlusion with immunoglobulin treatment
  • For subjects with an endovascular stent, the subject must receive documented medical clearance from a vascular surgeon stating that the subject is not at increased risk for thromboembolic events with immunoglobulin treatment

Main Exclusion Criteria:

  • Possible AD by NINCDS-ADRDA criteria or non-Alzheimer dementia (eg, vascular dementia, dementia with Lewy bodies, frontotemporal dementia, or dementia arising from other diseases or conditions such as Parkinson's disease, vitamin B12 deficiency, thyroid abnormalities)
  • Current residence in a skilled nursing facility
  • to undergoing MRI (eg, pacemaker [with the exception of an MRI-compatible pacemaker], severe claustrophobia, ferromagnetic implants such as a metal plate)
  • congestive heart failure (eg, [NYHA] Class III/IV symptoms or untreated Class II)
  • Current atrial fibrillation of unstable angina (angina at rest) or history of myocardial infarction within the 12 months prior to screening
  • Uncontrolled hypertension defined as systolic blood pressure > 160 mm Hg and/or diastolic > 100 mm Hg confirmed upon repeated measures
  • History of thrombosis and/or thromboembolic disease (central or peripheral) within the 12 months prior to screening
  • Known history of procoagulant abnormalities (eg, factor V Leiden, antiphospholipid syndrome, protein S/protein C deficiency, AT III deficiency)
  • History of intracerebral hemorrhage within the 5 years prior to screening
  • Evidence on MRI of: greater than 4 microhemorrhages (regardless of their anatomical location or diagnostic characterization as "possible" or "definite"), a single area of superficial siderosis, vasogenic edema, a macrohemorrhage, major stroke, prominent white matter disease with a rating score of 3 on the age-related white matter changes (ARWMC) scale from the European Task Force on ARWMC, or multiple lacunae (defined as more than 2 lacunae that are greater than 0.5 mm in size)
  • Head trauma with loss of consciousness, contusion, or open head injury within the 12 months prior to screening
  • Uncontrolled seizure disorder as defined by two or more breakthrough seizures per year despite adequate antiepileptic drug (AED) treatment
  • Modified Hachinski score > 4 at time of screening
  • Subjects with active or history of malignancy within 5 years prior to screening with the exception of the following: adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, and stable prostate cancer not requiring treatment
  • Active or neuro-immunologic disorder
  • Uncontrolled major depression, psychosis, or other major psychiatric disorder(s)
  • Poorly controlled diabetes, defined as glycosylated (or glycated) () ≥ 6.5% at screening
  • \< 50% of normal adjusted for age and gender, as calculated according to the Cockcroft-Gault formula, at the time of screening
  • Known history of untreated vitamin B12 deficiency within 6 months prior to screening, or clinically significant abnormally low vitamin B12 at the time of screening
  • Abnormal clinical chemistry panel or hematology panel meeting any one of the following criteria:
  • Serum (ALT) > 2.5 x (ULN)
  • Clinically significant anemia that precludes repeated blood sampling or hemoglobin (Hgb) \< 10.0 g/dL
  • (ANC) \< 1000 cells/µL
  • Known coagulopathy or counts \< 100,000 cells/µL
  • Total serum protein > 9 g/dL
  • Known history of or positive serology at screening for one or more of the following: surface antigen (HBsAg), virus (HCV) antibody, or (HIV) type 1/2 antibody
  • Immunoglobulin A (IgA) deficiency (\< 8 mg/dL)
  • Known history of following infusions of human blood or blood components (e.g. human immunoglobulins or human albumin)
  • Currently receiving or has received: anti-CD20 therapy within 12 months prior to screening, or other immunomodulatory therapies (e.g. anti-TNF, anti-IL-1, interferon) within 12 weeks prior to screening. The following exceptions are allowed: non-systemic (eg, topical, opthalmic or inhaled glucocorticoids) and low-dose systemic corticosteroids (prednisone \< 10 mg/day or its equivalent)
  • Currently receiving or has received intravenous or subcutaneous immunoglobulin treatment within the 2 years prior to screening, or has received immunoglobulin in Baxter Protocol 160701
  • Currently receiving or has received at any time active immunization aimed at modulating AD progression
  • Currently receiving or has received within 12 months prior to screening any device, drug or biologic (eg passive immunotherapies with monoclonal or polyclonal antibodies) aimed at modulating AD progression
  • Subject has been exposed to an investigational product (IP) or investigational device within 12 weeks prior to screening or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study
  • Subject is a family member or employee of the investigator
  • The subject is nursing or intends to begin nursing during the course of the study
  • Any disorder or disease, or clinically significant abnormality on laboratory or other clinical test(s) (eg, blood tests, urine tests, , chest x-ray), that in medical judgment may impede the subject's participation in the study, pose increased risk to the subject, or confound the results of the study
  • Currently receiving anti-coagulant agent and/or anti-platelet agent other than acetylsalicylic acid (a.k.a. aspirin)
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
508 participants (actual)

Study arms

  • Experimental
    IGIV, 10% at high dose (0.4 g/kg)

    Biological: Immune Globulin Intravenous (Human), 10% Solution

  • Experimental
    IGIV, 10% at low dose (0.2 g/kg)

    Biological: Immune Globulin Intravenous (Human), 10% Solution

  • Placebo comparator
    Placebo control

    Biological: Human albumin 0.25%

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Month 18 in Cognitive Subscale of the Alzheimer´s Disease Assessment Scale (ADAS-Cog)

    The ADAS-Cog is a validated psychometric instrument that evaluates memory (word recall, word recognition), attention, reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). This test was administered by experienced raters certified by Alzheimer's Disease Cooperative Study (ADCS) at each site. Scores on the ADAS-Cog range from 0-70 with higher scores indicating greater impairment; hence increases from baseline reflect potential cognitive deterioration.

    Time frame: Baseline to 9 Months (actual time frame)

  2. Change From Baseline to Month 18 in Alzheimer´s Disease Cooperative Study (ADCS)-Activities of Daily Living (ADL) Inventory

    The ADCS-ADL scale is a validated tool to assess instrumental and basic activities of daily living based on a 23 item structured interview of the caregiver or qualified study partner. Scores on the ADCS-ADL range from 0-78 with lower scores indicating greater impairment; hence decreases from baseline reflect potential functional deterioration.

    Time frame: Baseline to 9 Months (actual time frame)

Secondary outcomes

  1. ADCS-Clinical Global Impression of Change (CGIC) at 18 Months

    The ADCS-CGIC is a validated categorical measure of change in a participant's global clinical status between baseline and follow-up visits, based on interview of the participant and the caregiver by a skilled and experienced clinician who was blinded to treatment assignment. The ADCS-CGIC score is based on a 7-point Likert scale, ranging from 1 (marked improvement) to 7 (marked worsening).

    Time frame: Baseline to 9 Months (actual time frame)

  2. Change From Baseline to Month 18 in Neuropsychiatric Inventory (NPI)

    The NPI is a validated instrument used to assess behavioral psychopathology in AD; it evaluates the frequency and severity of 10 neuropsychiatric features including delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, aberrant motor activity, sleep and night-time behavior change, and appetite and eating change. The NPI total score ranged 0-144, with higher scores indicating greater impairment.

    Time frame: Baseline to 9 Months (actual time frame)

  3. Change From Baseline to Month 18 in Volumetric Magnetic Resonance Imaging (MRI) Parameters: Rate of Whole Brain Atrophy and Ventricular Enlargement

    Time frame: Baseline to 9 Months (actual time frame)

  4. Change From Baseline to Month 18 in Logsdon Quality of Life in Alzheimer´s Disease (QOL-AD)

    The QOL AD is a validated, 13-item instrument developed specifically for individuals with dementia. The assessment rates the participant´s quality of life for physical, emotional, interpersonal, and environmental domains. The QOL-AD total score ranged 13-52, with lower scores associated with a lower quality of life.

    Time frame: Baseline to 9 Months (actual time frame)

  5. Change From Baseline to Month 18 in Impact of Alzheimer´s Disease on Caregiver Questionnaire (IADCQ)

    The IADCQ is a 12-item validated questionnaire that has been developed to measure the emotional, physical, and social impact of care giving on AD caregivers. Higher scores on the IADCQ are associated with a higher impact. IADCQ total score range: 0 (no impact) - 48 (greatest impact). Each item can be scored either 0 (Not at all), 1 (A little), 2 (Somewhat), 3 (A lot), or 4 (Extremely). As this is a 12-item scale, the minimum possible score is 0 and the maximum possible score is 4x12 = 48.

    Time frame: Baseline to 9 Months (actual time frame)

  6. Number of Participants Experiencing Study Product-related Adverse Events (AEs) and/or Serious Adverse Events (SAEs)

    Time frame: Throughout the study period: 18 Months

  7. Number of Participants Experiencing Any AEs and/or SAEs

    Time frame: Throughout the study period: 18 Months

  8. Number of Infusions Temporally Associated With AEs and/or SAEs

    A temporal association was defined as an AE and/or SAE occurring during or within 72 hours of completion of an infusion, regardless of causality.

    Time frame: During or within 72 hours of completion of an infusion

  9. Number of Infusions Associated With AEs and/or SAEs Occurring During or Within 7 Days of Completion of an Infusion

    Time frame: During or within 7 days of completion of an infusion

  10. Number of Infusions Causally Associated With AEs and/or SAEs

    Time frame: Throughout the study period: 18 Months

  11. Number of Infusions Discontinued, Slowed, or Interrupted Due to an AE

    Time frame: Throughout infusions, approximately 2-5 hours

07

Results

Posted Mar 31, 2015
Limitations and caveats
The primary and secondary outcome measures were originally planned to be assessed at 18 months. However, as the study was terminated early, an analysis was completed at 9 months instead, in a subset of subjects who had received 9 months of treatment.

Participant flow

Enrollment was conducted at 58 clinical sites worldwide.

Participant flow — Overall Study
MilestoneIGIV, 10% at High Dose (0.4 g/kg)IGIV, 10% at Low Dose (0.2 g/kg)Placebo Control
Started859086
Received treatment838583
Completed000
Not completed859086
Withdrew: Withdrawal by subject623
Withdrew: Adverse event511
Withdrew: Protocol violation001
Withdrew: Study termination738779
Withdrew: Withdrawal by caregiver002
Withdrew: Use of prohibited medication100

Outcome measures

PrimaryChange From Baseline to Month 18 in Cognitive Subscale of the Alzheimer´s Disease Assessment Scale (ADAS-Cog)

The ADAS-Cog is a validated psychometric instrument that evaluates memory (word recall, word recognition), attention, reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). This test was administered by experienced raters certified by Alzheimer's Disease Cooperative Study (ADCS) at each site. Scores on the ADAS-Cog range from 0-70 with higher scores indicating greater impairment; hence increases from baseline reflect potential cognitive deterioration.

Time frame:
Baseline to 9 Months (actual time frame)
Reported as:
Mean · Scores on a scale
Change From Baseline to Month 18 in Cognitive Subscale of the Alzheimer´s Disease Assessment Scale (ADAS-Cog)
Scores on a scaleIGIV, 10% at High Dose (0.4 g/kg)IGIV, 10% at Low Dose (0.2 g/kg)Placebo Control
Change From Baseline to Month 18 in Cognitive Subscale of the Alzheimer´s Disease Assessment Scale (ADAS-Cog)4.0 ± 6.444.4 ± 8.563.1 ± 4.28
Statistical analysis
  • IGIV, 10% at High Dose (0.4 g/kg) vs Placebo Control · Mixed Models Analysis · p = 0.243 · Difference in least square means: 1.4 · 95% CI -1.0 to 3.9
  • IGIV, 10% at Low Dose (0.2 g/kg) vs Placebo Control · Mixed Models Analysis · p = 0.370 · Difference in least square means: 1.0 · 95% CI -1.2 to 3.3
PrimaryChange From Baseline to Month 18 in Alzheimer´s Disease Cooperative Study (ADCS)-Activities of Daily Living (ADL) Inventory

The ADCS-ADL scale is a validated tool to assess instrumental and basic activities of daily living based on a 23 item structured interview of the caregiver or qualified study partner. Scores on the ADCS-ADL range from 0-78 with lower scores indicating greater impairment; hence decreases from baseline reflect potential functional deterioration.

Time frame:
Baseline to 9 Months (actual time frame)
Reported as:
Mean · Scores on a scale
Change From Baseline to Month 18 in Alzheimer´s Disease Cooperative Study (ADCS)-Activities of Daily Living (ADL) Inventory
Scores on a scaleIGIV, 10% at High Dose (0.4 g/kg)IGIV, 10% at Low Dose (0.2 g/kg)Placebo Control
Change From Baseline to Month 18 in Alzheimer´s Disease Cooperative Study (ADCS)-Activities of Daily Living (ADL) Inventory-8.1 ± 7.36-5.0 ± 11.64-3.8 ± 9.26
Statistical analysis
  • IGIV, 10% at High Dose (0.4 g/kg) vs Placebo Control · Mixed Models Analysis · p = 0.033 · Difference in least square means: -3.9 · 95% CI -7.4 to -0.3
  • IGIV, 10% at Low Dose (0.2 g/kg) vs Placebo Control · Mixed Models Analysis · p = 0.586 · Difference in least square means: -0.9 · 95% CI -4.2 to 2.4
SecondaryADCS-Clinical Global Impression of Change (CGIC) at 18 Months

The ADCS-CGIC is a validated categorical measure of change in a participant's global clinical status between baseline and follow-up visits, based on interview of the participant and the caregiver by a skilled and experienced clinician who was blinded to treatment assignment. The ADCS-CGIC score is based on a 7-point Likert scale, ranging from 1 (marked improvement) to 7 (marked worsening).

Time frame:
Baseline to 9 Months (actual time frame)
Reported as:
Least squares mean · Scores on a scale
ADCS-Clinical Global Impression of Change (CGIC) at 18 Months
Scores on a scaleIGIV, 10% at High Dose (0.4 g/kg)IGIV, 10% at Low Dose (0.2 g/kg)Placebo Control
ADCS-Clinical Global Impression of Change (CGIC) at 18 Months4.3 (3.7 to 4.8)4.4 (4.0 to 4.9)4.5 (4.1 to 5.0)
Statistical analysis
  • IGIV, 10% at High Dose (0.4 g/kg) vs Placebo Control · Mixed Models Analysis · p = 0.501 · Difference in least square means: -0.2 · 95% CI -1.0 to 0.5
  • IGIV, 10% at Low Dose (0.2 g/kg) vs Placebo Control · Mixed Models Analysis · p = 0.783 · Difference in least square means: -0.1 · 95% CI -0.7 to 0.5
SecondaryChange From Baseline to Month 18 in Neuropsychiatric Inventory (NPI)

The NPI is a validated instrument used to assess behavioral psychopathology in AD; it evaluates the frequency and severity of 10 neuropsychiatric features including delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, aberrant motor activity, sleep and night-time behavior change, and appetite and eating change. The NPI total score ranged 0-144, with higher scores indicating greater impairment.

Time frame:
Baseline to 9 Months (actual time frame)
Reported as:
Mean · Scores on a scale
Change From Baseline to Month 18 in Neuropsychiatric Inventory (NPI)
Scores on a scaleIGIV, 10% at High Dose (0.4 g/kg)IGIV, 10% at Low Dose (0.2 g/kg)Placebo Control
Change From Baseline to Month 18 in Neuropsychiatric Inventory (NPI)2.3 ± 5.763.8 ± 12.440.6 ± 5.68
Statistical analysis
  • IGIV, 10% at High Dose (0.4 g/kg) vs Placebo Control · Mixed Models Analysis · p = 0.571 · Difference in least square means: 1.1 · 95% CI -2.6 to 4.7
  • IGIV, 10% at Low Dose (0.2 g/kg) vs Placebo Control · Mixed Models Analysis · p = 0.032 · Difference in least square means: 3.7 · 95% CI 0.3 to 7.1
SecondaryChange From Baseline to Month 18 in Volumetric Magnetic Resonance Imaging (MRI) Parameters: Rate of Whole Brain Atrophy and Ventricular Enlargement
Time frame:
Baseline to 9 Months (actual time frame)
Reported as:
Mean · mm^3
Change From Baseline to Month 18 in Volumetric Magnetic Resonance Imaging (MRI) Parameters: Rate of Whole Brain Atrophy and Ventricular Enlargement
mm^3IGIV, 10% at High Dose (0.4 g/kg)IGIV, 10% at Low Dose (0.2 g/kg)Placebo Control
Change From Baseline to Month 18 in Volumetric Magnetic Resonance Imaging (MRI) Parameters: Rate of Whole Brain Atrophy and Ventricular Enlargement0.00065 ± 0.000590.00057 ± 0.000700.00067 ± 0.00163
Statistical analysis
  • IGIV, 10% at High Dose (0.4 g/kg) vs Placebo Control · ANCOVA · p = 0.593 · Difference in least square means: -0.00026 · 95% CI -0.00126 to 0.00073
  • IGIV, 10% at Low Dose (0.2 g/kg) vs Placebo Control · ANCOVA · p = 0.940 · Difference in least square means: 0.00003 · 95% CI -0.00080 to 0.00086
SecondaryChange From Baseline to Month 18 in Logsdon Quality of Life in Alzheimer´s Disease (QOL-AD)

The QOL AD is a validated, 13-item instrument developed specifically for individuals with dementia. The assessment rates the participant´s quality of life for physical, emotional, interpersonal, and environmental domains. The QOL-AD total score ranged 13-52, with lower scores associated with a lower quality of life.

Time frame:
Baseline to 9 Months (actual time frame)
Reported as:
Mean · Scores on a scale
Change From Baseline to Month 18 in Logsdon Quality of Life in Alzheimer´s Disease (QOL-AD)
Scores on a scaleIGIV, 10% at High Dose (0.4 g/kg)IGIV, 10% at Low Dose (0.2 g/kg)Placebo Control
Change From Baseline to Month 18 in Logsdon Quality of Life in Alzheimer´s Disease (QOL-AD)-0.1 ± 4.430.4 ± 3.680.1 ± 4.56
Statistical analysis
  • IGIV, 10% at High Dose (0.4 g/kg) vs Placebo Control · Mixed Models Analysis · p = 0.633 · Difference in least square means: -0.5 · 95% CI -2.8 to 1.7
  • IGIV, 10% at Low Dose (0.2 g/kg) vs Placebo Control · Mixed Models Analysis · p = 0.981 · Difference in least square means: -0.0 · 95% CI -2.0 to 2.0
SecondaryChange From Baseline to Month 18 in Impact of Alzheimer´s Disease on Caregiver Questionnaire (IADCQ)

The IADCQ is a 12-item validated questionnaire that has been developed to measure the emotional, physical, and social impact of care giving on AD caregivers. Higher scores on the IADCQ are associated with a higher impact. IADCQ total score range: 0 (no impact) - 48 (greatest impact). Each item can be scored either 0 (Not at all), 1 (A little), 2 (Somewhat), 3 (A lot), or 4 (Extremely). As this is a 12-item scale, the minimum possible score is 0 and the maximum possible score is 4x12 = 48.

Time frame:
Baseline to 9 Months (actual time frame)
Reported as:
Mean · Scores on a scale
Change From Baseline to Month 18 in Impact of Alzheimer´s Disease on Caregiver Questionnaire (IADCQ)
Scores on a scaleIGIV, 10% at High Dose (0.4 g/kg)IGIV, 10% at Low Dose (0.2 g/kg)Placebo Control
Change From Baseline to Month 18 in Impact of Alzheimer´s Disease on Caregiver Questionnaire (IADCQ)5.8 ± 4.131.9 ± 6.661.4 ± 5.97
SecondaryNumber of Participants Experiencing Study Product-related Adverse Events (AEs) and/or Serious Adverse Events (SAEs)
Time frame:
Throughout the study period: 18 Months
Reported as:
Number · participants
Number of Participants Experiencing Study Product-related Adverse Events (AEs) and/or Serious Adverse Events (SAEs)
participantsIGIV, 10% at High Dose (0.4 g/kg)IGIV, 10% at Low Dose (0.2 g/kg)Placebo Control
Participants with product-related AEs (incl SAEs)312516
Participants with product-related non-serious AEs302516
Participants with product-related SAEs101
SecondaryNumber of Participants Experiencing Any AEs and/or SAEs
Time frame:
Throughout the study period: 18 Months
Reported as:
Number · participants
Number of Participants Experiencing Any AEs and/or SAEs
participantsIGIV, 10% at High Dose (0.4 g/kg)IGIV, 10% at Low Dose (0.2 g/kg)Placebo Control
Participants with AEs (incl SAEs)575449
Participants with non-serious AEs555348
Participants with serious AEs (SAEs)577
SecondaryNumber of Infusions Temporally Associated With AEs and/or SAEs

A temporal association was defined as an AE and/or SAE occurring during or within 72 hours of completion of an infusion, regardless of causality.

Time frame:
During or within 72 hours of completion of an infusion
Reported as:
Number · infusions
Number of Infusions Temporally Associated With AEs and/or SAEs
infusionsIGIV, 10% at High Dose (0.4 g/kg)IGIV, 10% at Low Dose (0.2 g/kg)Placebo Control
Number of Infusions Temporally Associated With AEs and/or SAEs728047
SecondaryNumber of Infusions Associated With AEs and/or SAEs Occurring During or Within 7 Days of Completion of an Infusion
Time frame:
During or within 7 days of completion of an infusion
Reported as:
Number · infusions
Number of Infusions Associated With AEs and/or SAEs Occurring During or Within 7 Days of Completion of an Infusion
infusionsIGIV, 10% at High Dose (0.4 g/kg)IGIV, 10% at Low Dose (0.2 g/kg)Placebo Control
Number of Infusions Associated With AEs and/or SAEs Occurring During or Within 7 Days of Completion of an Infusion9710772
SecondaryNumber of Infusions Causally Associated With AEs and/or SAEs
Time frame:
Throughout the study period: 18 Months
Reported as:
Number · infusions
Number of Infusions Causally Associated With AEs and/or SAEs
infusionsIGIV, 10% at High Dose (0.4 g/kg)IGIV, 10% at Low Dose (0.2 g/kg)Placebo Control
Number of Infusions Causally Associated With AEs and/or SAEs464830
SecondaryNumber of Infusions Discontinued, Slowed, or Interrupted Due to an AE
Time frame:
Throughout infusions, approximately 2-5 hours
Reported as:
Number · infusions
Number of Infusions Discontinued, Slowed, or Interrupted Due to an AE
infusionsIGIV, 10% at High Dose (0.4 g/kg)IGIV, 10% at Low Dose (0.2 g/kg)Placebo Control
Number of Infusions Discontinued, Slowed, or Interrupted Due to an AE721

Adverse events

Collected over Throughout the study period. The study was terminated early and no subject completed 18 months of treatment as planned per protocol. The duration of exposure to the investigational product varied for each subject.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IGIV, 10% at High Dose (0.4 g/kg)—5/83 (6%)30/83 (36.1%)
IGIV, 10% at Low Dose (0.2 g/kg)—7/85 (8.2%)33/85 (38.8%)
Placebo Control—7/83 (8.4%)30/83 (36.1%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventIGIV, 10% at High Dose (0.4 g/kg)IGIV, 10% at Low Dose (0.2 g/kg)Placebo Control
DehydrationMetabolism and nutrition disorders0/830/852/83
Breast CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/830/852/83
Angina PectorisCardiac disorders1/830/851/83
Food PoisoningGastrointestinal disorders0/830/851/83
Gastroenteritis ViralInfections and infestations0/830/851/83
Human EhrlichiosisInfections and infestations1/830/850/83
PneumoniaInfections and infestations1/830/850/83
Urinary Tract InfectionInfections and infestations1/830/850/83
EncephalopathyNervous system disorders1/830/850/83
HeadacheNervous system disorders1/830/850/83
Most frequent other events
Most frequent other events
EventIGIV, 10% at High Dose (0.4 g/kg)IGIV, 10% at Low Dose (0.2 g/kg)Placebo Control
HeadacheNervous system disorders10/8311/855/83
DiarrhoeaGastrointestinal disorders1/830/8510/83
FatigueGeneral disorders5/8310/856/83
RashSkin and subcutaneous tissue disorders7/838/851/83
Infusion Site ExtravasationGeneral disorders5/836/854/83
Back PainMusculoskeletal and connective tissue disorders5/835/853/83
NauseaGastrointestinal disorders5/835/853/83
Upper Respiratory Tract InfectionInfections and infestations3/835/855/83
NasopharyngitisInfections and infestations0/833/855/83
Pain in ExtremityMusculoskeletal and connective tissue disorders5/831/850/83

Baseline characteristics

The baseline analysis population comprises treated subjects (=safety analysis set).

Age, Continuous
Age, Continuous(years)IGIV, 10% at High Dose (0.4 g/kg)IGIV, 10% at Low Dose (0.2 g/kg)Placebo ControlTotal
Mean72.0 ± 8.3669.9 ± 8.5970.6 ± 9.9870.8 ± 9.01
Sex: Female, Male
Sex: Female, Male(Participants)IGIV, 10% at High Dose (0.4 g/kg)IGIV, 10% at Low Dose (0.2 g/kg)Placebo ControlTotal
Female433752132
Male404831119
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IGIV, 10% at High Dose (0.4 g/kg)IGIV, 10% at Low Dose (0.2 g/kg)Placebo ControlTotal
American Indian or Alaska Native0101
Asian0134
Native Hawaiian or Other Pacific Islander1012
Black or African American1315
White817978238
More than one race0101
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)IGIV, 10% at High Dose (0.4 g/kg)IGIV, 10% at Low Dose (0.2 g/kg)Placebo ControlTotal
United States666766199
Canada87722
Spain35311
Belgium65617
Japan0112
08

Study locations

69 sites
  • Birmingham, Alabama, United States
  • Phoenix, Arizona, United States
  • Long Beach, California, United States
  • San Diego, California, United States
  • Santa Ana, California, United States
  • Boca Raton, Florida, United States
  • Delray Beach, Florida, United States
  • Edgewater, Florida, United States
  • Orlando, Florida, United States
  • Decatur, Georgia, United States
  • Chicago, Illinois, United States
  • Springfield, Illinois, United States
  • Paducah, Kentucky, United States
  • Saint Paul, Minnesota, United States
  • Olive Branch, Mississippi, United States
  • Las Vegas, Nevada, United States
  • Berlin, New Jersey, United States
  • Chester, New Jersey, United States
  • Eatontown, New Jersey, United States
  • Summit, New Jersey, United States
  • Toms River, New Jersey, United States
  • Albany, New York, United States
  • Brooklyn, New York, United States
  • Latham, New York, United States
  • Manhasset, New York, United States
  • New Hyde Park, New York, United States
  • Cincinnati, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Tulsa, Oklahoma, United States
  • Providence, Rhode Island, United States
  • Austin, Texas, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Bennington, Vermont, United States
  • Charlottesville, Virginia, United States
  • Milwaukee, Wisconsin, United States
  • Woodville South, South Australia, Australia
  • Edegem, Belgium
  • Gent, Belgium
  • Hasselt, Belgium
  • Leuven, Belgium
  • Roeselare, Belgium
  • Toronto, Ontario, Canada
  • Greenfield Park, Quebec, Canada
  • Sherbrooke, Quebec, Canada
  • Akashi, Japan
  • Akita, Japan
  • Azumino, Japan
  • Chiba, Japan
  • Fukui, Japan
  • Kyoto, Japan
  • Niigata, Japan
  • Osaka, Japan
  • Saga, Japan
  • Tokushima, Japan
  • Tokyo, Japan
  • Lublin, Poland
  • Scinawa, Poland
  • Warszawa, Poland
  • Barakaldo, Vizcaya, Spain
  • Barcelona, Spain
  • Madrid, Spain
  • Valencia, Spain
  • Uckfield, East Sussex, United Kingdom
  • Bath, United Kingdom
  • Brentford, United Kingdom
  • Brighton, United Kingdom
  • Glasgow, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2012 to primary completion in Jul 2013, 17 months.

Results were first posted in Mar 2015, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2012
First posted
Feb 2, 2012
StartActual
Jan 23, 2012
Primary completionActual
Jul 16, 2013
CompletionActual
Jul 16, 2013
Results first posted
Mar 31, 2015
Last update
May 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01524887
Responsible party
Sponsor
First posted
Feb 2, 2012
Start date
Jan 23, 2012
Primary completion
Jul 16, 2013
Completion
Jul 16, 2013
Results posted
Mar 31, 2015
Last update
May 19, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion